PE20121276A1 - Compuestos espirociclicos que contienen nitrogeno y su uso medicinal - Google Patents

Compuestos espirociclicos que contienen nitrogeno y su uso medicinal

Info

Publication number
PE20121276A1
PE20121276A1 PE2012000097A PE2012000097A PE20121276A1 PE 20121276 A1 PE20121276 A1 PE 20121276A1 PE 2012000097 A PE2012000097 A PE 2012000097A PE 2012000097 A PE2012000097 A PE 2012000097A PE 20121276 A1 PE20121276 A1 PE 20121276A1
Authority
PE
Peru
Prior art keywords
halogen
compounds containing
containing nitrogen
alkyl
medicinal use
Prior art date
Application number
PE2012000097A
Other languages
English (en)
Inventor
Satoru Noji
Makoto Shiozaki
Tomoya Miura
Yoshinori Hara
Hiroshi Yamanaka
Katsuya Maeda
Akimi Hori
Masafumi Inoue
Yasunori Hase
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529436&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121276(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20121276A1 publication Critical patent/PE20121276A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE Ra ES ALQUILO C1-C6, HALOGENO; n1 ES 0-4; Rb ES ALQUILO C1-C6, HALOGENO; n2 ES 0-4; m1 ES 0-3; m2 ES 1-4; Xa=Xb ES CH=CH, N=CH, CH=N; X ES N, CH, C-(HALOGENO); Rc ES H, ALQUILO C1-C6 SUSTITUIDO O NO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-OXO-3-[7-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1,7-DIAZAESPIRO[4,5]DEC-1-IL]PROPIONITRILO; 3-[3-METIL-6-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1,6-DIAZAESPIRO[3,4]OCT-1-IL]-3-OXOPROPIONITRILO; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE CINASA JANUS 2 UTILES EN EL TRATAMIENTO DE RECHAZO DE TRASPLANTE DE ORGANOS, ENFERMEDAD AUTOINMUNE, ENFERMEDADES ALERGICAS, ENFERMEDAD MIELOPROLIFERATIVA CRONICA, ARTRITIS REUMATOIDEA
PE2012000097A 2009-07-31 2010-07-30 Compuestos espirociclicos que contienen nitrogeno y su uso medicinal PE20121276A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009179502 2009-07-31
US27413709P 2009-08-13 2009-08-13

Publications (1)

Publication Number Publication Date
PE20121276A1 true PE20121276A1 (es) 2012-09-27

Family

ID=43529436

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000097A PE20121276A1 (es) 2009-07-31 2010-07-30 Compuestos espirociclicos que contienen nitrogeno y su uso medicinal

Country Status (31)

Country Link
US (4) US8609647B2 (es)
EP (3) EP2460806B1 (es)
JP (8) JP5520158B2 (es)
KR (1) KR101773208B1 (es)
CN (1) CN102510865B (es)
AR (1) AR077497A1 (es)
AU (1) AU2010278066B2 (es)
BR (1) BR112012002157B1 (es)
CA (1) CA2767899C (es)
CO (1) CO6491052A2 (es)
CY (1) CY1118747T1 (es)
DK (1) DK2460806T3 (es)
ES (1) ES2616705T3 (es)
HR (1) HRP20170447T1 (es)
HU (1) HUE033070T2 (es)
IL (1) IL217048A (es)
LT (1) LT2460806T (es)
ME (1) ME02667B (es)
MX (1) MX2012001313A (es)
MY (1) MY163495A (es)
NZ (1) NZ597994A (es)
PE (1) PE20121276A1 (es)
PL (1) PL2460806T3 (es)
PT (1) PT2460806T (es)
RS (1) RS55913B1 (es)
RU (1) RU2630694C2 (es)
SG (1) SG176918A1 (es)
SI (1) SI2460806T1 (es)
TW (1) TWI466885B (es)
WO (1) WO2011013785A1 (es)
ZA (1) ZA201200689B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
NZ606751A (en) * 2010-08-20 2015-04-24 Hutchison Medipharma Ltd Pyrrolopyrimidine compounds and uses thereof
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
AU2012357296B2 (en) 2011-12-21 2017-04-13 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
JP6427497B2 (ja) * 2013-10-21 2018-11-21 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
AU2015265696B2 (en) * 2014-05-28 2018-01-18 Astrazeneca Ab Processes for the preparation of AZD5363 and novel intermediate used therein
WO2017006968A1 (ja) 2015-07-07 2017-01-12 日本たばこ産業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン誘導体の製造方法及びその中間体
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
RU2754997C2 (ru) * 2015-09-24 2021-09-08 Лео Фарма А/С Лечение очаговой алопеции
EP4219482A1 (en) * 2015-09-25 2023-08-02 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Compounds and methods for inhibiting jak
IL297379A (en) 2016-01-21 2022-12-01 Leo Pharma As Treatment of hand eczema
JP6937828B2 (ja) * 2016-11-23 2021-09-22 江蘇恒瑞医薬股▲ふん▼有限公司 ピロロ６員複素芳香環誘導体の製造方法、および中間体
CN110099910B (zh) * 2016-12-21 2022-12-20 日本烟草产业株式会社 7H-吡咯并[2,3-d]嘧啶衍生物的制备方法及其共晶
US11339181B2 (en) 2016-12-21 2022-05-24 Japan Tobacco Inc. Crystalline forms of a Janus kinase inhibitor
TWI816651B (zh) * 2016-12-21 2023-10-01 日商日本煙草產業股份有限公司 7H-吡咯并[2,3-d]嘧啶衍生物的製造方法及其合成中間體
RU2764980C2 (ru) * 2017-01-20 2022-01-24 Лео Фарма А/С Бициклические амины в качестве новых ингибиторов jak-киназы
US10799507B2 (en) * 2017-02-03 2020-10-13 Leo Pharma A/S 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors
AU2018347349A1 (en) * 2017-10-10 2020-04-23 Biogen Inc. Process for preparing spiro derivatives
SG11202007251XA (en) * 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
BR112021022031A2 (pt) 2019-05-15 2021-12-28 Leo Pharma As Composto, composição farmacêutica, e, formulação farmacêutica para administração tópica
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
EP4070796A4 (en) * 2019-12-27 2024-01-17 Rohto Pharma AQUEOUS COMPOSITION
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN114591321A (zh) * 2020-12-04 2022-06-07 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途
WO2022143629A1 (zh) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 治疗与抗肿瘤剂相关的皮肤疾病或病症的试剂和方法
WO2023202989A1 (en) 2022-04-20 2023-10-26 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00011889A (es) 1998-06-02 2003-04-25 Osi Pharm Inc Composiciones de pirrolo (2,3d) piridina y su uso.
KR100415791B1 (ko) * 1998-06-19 2004-01-24 화이자 프로덕츠 인코포레이티드 피롤로[2,3-디]피리미딘 화합물
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2001042246A2 (en) 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
NZ537214A (en) * 2002-07-05 2007-08-31 Targacept Inc N-Aryl diazaspiracyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof
WO2005047286A1 (ja) 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2598956A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
EP1881983B1 (en) 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
TWI468162B (zh) 2005-12-13 2015-01-11 英塞特公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2008029237A2 (en) 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
JP2010513385A (ja) 2006-12-22 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ピペリジン誘導体
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
BRPI0809992A2 (pt) * 2007-04-02 2014-10-14 Palau Pharma Sa Derivados de pirrolopirimidina
US20100298289A1 (en) * 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
PE20091315A1 (es) 2008-01-09 2009-09-21 Array Biopharma Inc Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
AU2009266806A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. CDK modulators
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
JP2018028525A (ja) * 2016-08-15 2018-02-22 小野　信行 イオンレーザーと重水素を利用した核融合炉
JP6229778B2 (ja) * 2016-09-21 2017-11-15 サミー株式会社 遊技機

Also Published As

Publication number Publication date
JP2018111701A (ja) 2018-07-19
ZA201200689B (en) 2012-10-31
US20140187534A1 (en) 2014-07-03
CN102510865A (zh) 2012-06-20
MX2012001313A (es) 2012-02-29
AR077497A1 (es) 2011-08-31
JP2011046700A (ja) 2011-03-10
LT2460806T (lt) 2017-02-10
JP2020033384A (ja) 2020-03-05
JP2016029104A (ja) 2016-03-03
NZ597994A (en) 2013-08-30
JP2021183653A (ja) 2021-12-02
EP3858349A1 (en) 2021-08-04
EP2460806B1 (en) 2017-01-04
HUE033070T2 (hu) 2017-11-28
AU2010278066A1 (en) 2012-03-01
MY163495A (en) 2017-09-15
JP2014141516A (ja) 2014-08-07
US20110136778A1 (en) 2011-06-09
PL2460806T3 (pl) 2017-06-30
TW201107325A (en) 2011-03-01
DK2460806T3 (en) 2017-03-20
BR112012002157B1 (pt) 2022-02-08
SG176918A1 (en) 2012-01-30
JP5520158B2 (ja) 2014-06-11
CA2767899C (en) 2018-08-28
SI2460806T1 (sl) 2017-04-26
WO2011013785A1 (ja) 2011-02-03
EP3181570A1 (en) 2017-06-21
EP2460806A4 (en) 2012-12-26
KR101773208B1 (ko) 2017-08-31
US20230023377A1 (en) 2023-01-26
BR112012002157A2 (pt) 2020-08-18
RU2630694C2 (ru) 2017-09-12
CN102510865B (zh) 2015-04-15
CY1118747T1 (el) 2017-07-12
JP2017019877A (ja) 2017-01-26
RS55913B1 (sr) 2017-09-29
PT2460806T (pt) 2017-02-27
US20240150367A1 (en) 2024-05-09
IL217048A (en) 2014-12-31
KR20120051649A (ko) 2012-05-22
RU2012106344A (ru) 2013-08-27
IL217048A0 (en) 2012-02-29
ME02667B (me) 2017-06-20
US8609647B2 (en) 2013-12-17
ES2616705T3 (es) 2017-06-14
EP2460806A1 (en) 2012-06-06
HRP20170447T1 (hr) 2017-05-19
JP2023138641A (ja) 2023-10-02
CO6491052A2 (es) 2012-07-31
TWI466885B (zh) 2015-01-01
AU2010278066B2 (en) 2016-04-14
CA2767899A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
PE20121276A1 (es) Compuestos espirociclicos que contienen nitrogeno y su uso medicinal
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
RU2013129820A (ru) Замещенные бензопиразиновые производные в качестве ингибиторов fgfr-киназ для лечения раковых заболеваний
ECSP13012703A (es) Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CL2013003647A1 (es) Compuestos derivados de pirrolo[2,3-d] pirimidina o pirrolo[2,3-b]piridina, inhibidores de la actividad de jak; composicion farmaceutica; utiles para el tratamiento de enfermedades autoinmunitarias, inflamatorias y de reabsorcion osea, cancer, trastornos mieloproliferativos o rechazo a trasplante de organos.
PE20141973A1 (es) Compuestos de heterociclilo como inhibidores de mek
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
PE20170663A1 (es) Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
PE20141938A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CO6630187A2 (es) 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20080931A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
CL2012000917A1 (es) Compuestos derivados de pirazolo [3,4-d] pirimidina, inhibidores btk; y uso en el tratamiento del cancer, enfermedades autoinmune, mastocitosis,osteoporosis,entre otras.
EA201201052A1 (ru) Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
UY30094A1 (es) Compuestos químicos
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k

Legal Events

Date Code Title Description
FG Grant, registration